CME Haematology or whose disease had progressed to the accelerated or blastic phase
rapidly led to its study as a new treatment option for patients in early CP. 5, 6 A recent five …

Imatinib at 400 mg per day has rapidly become the standard therapy for newly diagnosed
patients with chronic phase chronic myeloid leukemia (CML). In this patient population, 74 …

A diagnosis of chronic myeloid leukemia (CML) remains unwelcome news. Thanks to
imatinib, however, the majority of newly diagnosed patients with chronic phase CML achieve …

Chronic myelogenous leukemia (CML) results from clonal proliferation of malignant
hematologic progenitor cells and is responsible for 7% to 15% of all adult leukemias. The …

Purpose To provide primary care providers with guidelines on the evaluation and manage‐
ment of treatment for patients with chronic myelogenous leukemia (CML) with emphasis on …

The clinical success of imatinib in patients with chronic myeloid leukemia (CML), which was
first reported 9 years ago, 1 catalyzed a systemwide shift in the development of cancer drugs …

Substantial progress has been made in the management of chronic phase CML (CML-CP).
The advent of imatinib mesylate (Gleevec) has changed the landscape of care and …

Leukaemia patients in Europe now have an important new treatment option. On 7 November
2001, the tyrosine kinase inhibitor imatinib mesylate (Glivec, previously STI-571) was …

The 5-year IRIS (International Randomized study of Interferon vs STI571) data, confirming
the excellent results with imatinib for chronic myeloid leukaemia (CML), were a highlight at …

The elucidation of the triggering molecular mechanism of chronic myeloid leukemia gave
rise to the development of imatinib, a tyrosine kinase inhibitor and a prototype of target …